liveBook · Manning

Hit

As explained in Build AI Drug Discovery Pipelines

A hit is a compound that shows measurable binding or activity against a selected biological target during discovery screening.

A hit is a compound that shows measurable binding affinity or activity against a selected biological target during discovery screening. Screening may be computational, such as virtual screening, or experimental, such as high-throughput assays. section 1.4.1

The target-to-hit stage searches a large, diverse compound library for molecules that attach to the target and may change its function. For an enzyme, an inhibitor can block conversion of a substrate into a product; unintended binding to other biomolecules is an off-target effect. section 1.4.1

Hits are provisional discoveries, not finished drug candidates:

  • Multiple hits usually undergo in vitro, confirmatory, and ADMET assays before the most promising compounds become leads. section 1.4.2
  • Assessment considers potency, efficacy, selectivity, pharmacokinetic properties, pharmacodynamic properties, and toxicity. section 1.4.2
  • Lead optimization modifies promising compounds while retaining their core molecular structure to improve potency, selectivity, and ADMET properties. section 1.4.2

Virtual screening for antimalarial hits

A virtual-screening pipeline can search a compound library for molecules with promising antimalarial activity, narrowing a large chemical space to candidates for subsequent testing. section 2.1

Figure 1.13 We can segment the early drug discovery pipeline into four main phases: target identification, hit discovery, hit-to-lead or lead identification, and lead optimization. Target identification designates a valid target whose activity is worth modulating to address some disease or disorder. Hit discovery uncovers chemical compounds with activity against the target. Lead identification selects the most promising hits and lead optimization improves their potency, selectivity, and ADMET properties to be suitable for preclinical study.

Use the early-discovery pipeline to place hit discovery between target identification and lead identification or optimization. section 1.4.2

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Defines screening and downstream assessment, but stops short of detailed assay protocols or molecular modeling internals.
Examples
Uses enzyme inhibitors, kinase inhibitors, compound libraries, and antimalarial virtual screening as concrete examples.
What it assumes
Assumes a selected biological target and compound library while defining binding, activity, potency, selectivity, and ADMET terms.
What you can do after
Apply via virtual or experimental screening to identify compounds for confirmatory assays and lead selection.
How it connects
Connects target identification, virtual screening, high-throughput screening, lead identification, lead optimization, ADMET, potency, and selectivity.

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.